In this prospective trial in oligometastatic renal cell carcinoma (RCC), the first of its kind, stereotactic ablative body radiotherapy was delivered successfully in lieu of systemic therapy. This strategy should be considered in selected patients with oligometastatic RCC.
This is a preview of subscription content
Access options
Subscribe to Nature+
Get immediate online access to the entire Nature family of 50+ journals
$29.99
monthly
Subscribe to Journal
Get full journal access for 1 year
$59.00
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Buy article
Get time limited or full article access on ReadCube.
$32.00
All prices are NET prices.
References
Barney, J. D. & Churchill, E. J. Adenocarcinoma of the kidney with metastasis to the lung: cured by nephrectomy and lobectomy. J. Urol. 42, 269–276 (1939).
Siva, S. et al. Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach. Nat. Rev. Urol. 14, 549–563 (2017).
Deschavanne, P. J. & Fertil, B. A review of human cell radiosensitivity in vitro. Int. J. Radiat. Oncol. Biol. Phys. 34, 251–266 (1996).
Zaorsky, N. G., Lehrer, E. J., Kothari, G., Louie, A. V. & Siva, S. Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies. Eur. Urol. Oncol. 2, 515–523 (2019).
Motzer, R. J. et al. Kidney cancer, version 2.2017, NCCN clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw. 15, 804–834 (2017).
Tang, C. et al. Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial. Lancet Oncol. 22, 1732–1739 (2021).
Rini, B. I. et al. Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Lancet Oncol. 17, 1317–1324 (2016).
Cheung, P. et al. Stereotactic radiotherapy for oligoprogression in metastatic renal cell cancer patients receiving tyrosine kinase inhibitor therapy: a phase 2 prospective multicenter study. Eur. Urol. 80, 693–700 (2021).
Turgeon, G.-A., Weickhardt, A., Azad, A. A., Solomon, B. & Siva, S. Radiotherapy and immunotherapy: a synergistic effect in cancer care. Med. J. Aust. 210, 47–53 (2019).
Siva, S. et al. Stereotactic radiotherapy and short-course pembrolizumab for oligometastatic renal cell carcinoma — the RAPPORT trial. Eur. Urol. https://doi.org/10.1016/j.eururo.2021.12.006 (2021).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
S.S. has received honoraria from AstraZeneca for Speaker’s Bureau and Advisory board, and research grants from Varian Industries. A.V.L. has received honoraria from AstraZeneca for Speaker’s Bureau and Advisory board.
Rights and permissions
About this article
Cite this article
Siva, S., Louie, A.V. Substituting SABR for systemic therapy in oligometastatic renal cell carcinoma — buying time or time to change?. Nat Rev Urol 19, 197–198 (2022). https://doi.org/10.1038/s41585-021-00560-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-021-00560-3
